German radiopharmaceutical firm ITM Isotopen Technologies Munich is partnering with Scil Proteins to develop novel, targeted radioconjugates for imaging and therapy purposes.
Scil Proteins will be responsible for the discovery and design of the radioconjugates based on its proprietary Affilin platform, while ITM will use its radioisotope technology for later-stage development and commercialization of the resulting products. The first program has commenced in the area of targeted cancer treatment.
Radioconjugates are biomolecules that can be radiolabeled in order to deliver diagnostic and therapeutic treatment applications.
